SCHEMBL20138261

SCHEMBL20138261

Cc1nn(C)c(C)c1CN1C(=O)CCc2ncc(Cl)cc21

nearest known ligand 0.34

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.34
KMT2A Q03164 3/20 0.34
NPC1 O15118 2/20 0.34
ALDH1A1 P00352 3/20 0.34
FPR2 P25090 3/20 0.33
PROKR1 Q8TCW9 3/20 0.33
SMN1; SMN2 Q16637 2/20 0.32
LMNA P02545 2/20 0.32
MEN1 O00255 2/20 0.32
PABPC1 P11940 1/20 0.32
TTR P02766 1/20 0.32
ADRA1B P35368 1/20 0.32
MAPT P10636 1/20 0.32
P2RX7 Q99572 1/20 0.31
POLB P06746 1/20 0.31
TP53 P04637 1/20 0.31
SHMT2 P34897 1/20 0.31
EZH2 Q15910 1/20 0.31
HTT P42858 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18305061 0.82 FPR2 (0.33) RAB9AKMT2ANPC1ALDH1A1FPR2
SCHEMBL20137926 0.79 CYP11B2 (0.44)
SCHEMBL20137987 0.77 CYP11B1 (0.39) FPR2PROKR1MAPT
SCHEMBL18305169 0.76 KCNH2 (0.39) RAB9ANPC1ALDH1A1SMN1; SMN2LMNA
SCHEMBL20138249 0.75 FYN (0.38)
SCHEMBL16823669 0.75 POLB (0.54) KMT2AALDH1A1SMN1; SMN2LMNAMEN1
SCHEMBL18305147 0.74 MAPK1 (0.39)
SCHEMBL20137959 0.68 RAB9A (0.37) RAB9AKMT2ANPC1ALDH1A1SMN1; SMN2
SCHEMBL16663607 0.67 POLB (0.52) KMT2AALDH1A1SMN1; SMN2MEN1POLB
SCHEMBL20138278 0.64 TSHR (0.35) RAB9AKMT2ANPC1ALDH1A1FPR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107873031-B Benzoxazinone derivatives and analogs thereof as modulators of TNF activity UCB生物制药私人有限公司 2021-03-12 CN disclosed
US-10287299-B2 Substituted benzo[b][1,4]oxazines and pyrido[3,2-b][1,4]oxazines as modulators of tumor necrosis factor activity UCB BIOPHARMA SPRL (BE) 2019-05-14 US disclosed
US-20180134728-A1 Benzoxazinone Derivatives and Analogues Thereof as Modulators of TNF Activity UCB S.A. (BE) 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180134728-A1 Benzoxazinone Derivatives and Analogues Thereof as Modulators of TNF Activity TNF, NFKBIA, TNFRSF1A RAB9A 1652/4885KMT2A 3814/4885NPC1 4103/4885
US-10287299-B2 Substituted benzo[b][1,4]oxazines and pyrido[3,2-b][1,4]oxazines as modulators of tumor necrosis factor activity TNF, TNFRSF1A, NFKBIA RAB9A 1873/4885KMT2A 3061/4885NPC1 4360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.